Tagged with RWE

Opinion Nigel Hughes of the European Health Data & Evidence Network (EHDEN) outlines EHDEN’s scope and purpose and highlights why greater collaboration on real-world data (RWD) will be crucial to ensuring better global health outcomes.    Ultimately, EHDEN is striving to ensure 21st century research can be conducted with 21st century…

Opinion Ulrich Neumann of Certara outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make on the global biopharma industry.   While the collection of real-world data is not new, real-world evidence is poised to have a profound impact on the biopharma industry…

Opinion Holmusk’s Nawal Roy highlights the increasing recognition of the value of real-world evidence (RWE) by both innovative pharma companies and drug regulators and its potential to increase market capture and profitability.   RWE has the potential to expand the market size of a disease and accelerate market capture of a…